Cancer Hormone Therapy Drugs Market Size in 2022, Increasing demand, Growth strategies, Forecast to 2028

Hormone Therapy, (also called hormonal therapy, hormone treatment, or endocrine therapy) is a cancer treatment that blocks or lowers the growth of cancer that uses hormones to grow. Doctors use it to treat some cancers such as breast and prostate cancer.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Cancer Hormone Therapy Drugs estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Cancer Hormone Therapy Drugs is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Cancer Hormone Therapy Drugs is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Cancer Hormone Therapy Drugs is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Cancer Hormone Therapy Drugs include Roche, Amgen, Pfizer, Teva, Takeda, Samyang Biopharmaceuticals, Tolmar, AstraZeneca and Novartis, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.